Namilumab

Namilumab ^?
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CSF2
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	1226761-65-4^N
ATC code	None
UNII	MED485W763^Y
Chemical data
Formula	?
N(what is this?) (verify)

Namilumab is an immunomodulator. It binds to CSF2.^[1]

References

^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information 24 (4). http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab immune activation: Ipilimumab • Tremelimumab other: Bertilimumab • Zanolimumab

Mouse ("-limo-")	Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab • Apolizumab • Benralizumab^† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140^† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab • Fanolesomab^‡ • Lemalesomab • Sulesomab

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)